LA ROCHE-POSAY

Main information

  • Trade name:
  • LA ROCHE-POSAY LABORATOIRE DERMATOLOGIQUE ANTHELIOS XL SPF50+ SPRAY
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • LA ROCHE-POSAY LABORATOIRE DERMATOLOGIQUE ANTHELIOS XL SPF50+ SPRAY
    Australia
  • Language:
  • English

Other information

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 213849
  • Last update:
  • 09-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:

213849

LA ROCHE-POSAY LABORATOIRE DERMATOLOGIQUE ANTHELIOS XL SPF50+ SPRAY

ARTG entry for

Medicine Listed

Sponsor

L'Oreal Australia Pty Ltd

Postal Address

PO Box 6813,ST KILDA ROAD CENTRAL, VIC, 3004

Australia

ARTG Start Date

26/08/2013

Product category

Medicine

Status

Active

Approval area

Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine,

(b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is

sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be

kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records

to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted

in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office

of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors

of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified

of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine

outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National

Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1. LA ROCHE-POSAY LABORATOIRE DERMATOLOGIQUE ANTHELIOS XL SPF50+ SPRAY

Product Type

Single Medicine Product

Effective date

26/08/2013

Warnings

Avoid prolonged exposure in the sun.[or words to that effect]

Wear protective clothing, hats and eyewear when exposed to the sun.[Or words to this effect]

Contains ethanol. (or words to that effect).

Avoid contact with eyes (or words to that effect).

Standard Indications

Broad Spectrum Sunscreen

A broad spectrum sunscreening preparation of SPF4 or greater. Can aid in the prevention of premature skin ageing.

A broad spectrum sunscreening preparation of SPF50+. Can aid in the prevention of sunspots

A broad spectrum sunscreening preparation of SPF50+. Can aid in the prevention of solar keratoses

A broad spectrum sunscreening preparation of SPF50+. May reduce the risk of some skin cancers

A broad spectrum sunscreening preparation of SPF50+. May assist in preventing some skin cancers

Sunscreen SPF50 Plus

Specific Indications

No Specific Indications included on Record

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1. Formulation 1

Dosage Form

Spray

Route of Administration

Topical

Visual Identification

Public Summary

Page 1 of

Produced at 24.11.2017 at 02:14:39 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

Active Ingredients

bemotrizinol

30 mg/g

butyl methoxydibenzoylmethane

30 mg/g

Drometrizole trisiloxane

30 mg/g

Ecamsule

9.9 mg/g

ethylhexyl triazone

25 mg/g

octyl salicylate

50 mg/g

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 2 of

Produced at 24.11.2017 at 02:14:39 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information